Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study

Abstract

SAFit-1 and SAFit-2 are selective FKBP51 (FK506-binding protein 51) ligands. In this paper, we present the development and validation data of an LC-MS/MS method for the simultaneous quantitation of SAFit-1 and SAFit-2 in mice plasma as per FDA regulatory guideline. SAFit-1 and SAFit-2 along with internal standard were extracted from mice plasma using liquid-liquid extraction method. Chromatographic resolution of SAFit-1, SAFit-2 and the internal standard (warfarin) was achieved on an X-Terra phenyl column using 0.2% formic acid:acetonitrile (20:80, v/v) as an eluent, which was delivered at a flow-rate of 0.9 mL/min. The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively. The linearity range was 2.45–2446 ng/mL for both SAFit-1 and SAFit-2. The intra- and inter-day accuracy and intra- and inter-day precision were in the range of 0.90–1.07 and 2.38–10.8%, respectively for SAFit-1; 0.97–1.15 and 0.23–12.5%, respectively for SAFit-2. Both SAFit-1 and SAFit-2 were found to be stable in stability studies (up to three freeze-thaw cycles and for long-term at −80°C for 30 days) and processed (bench-top for 3 h and in in-injector for 16 h) samples. The application of the validated method was shown in a pharmacokinetic study in mice.

Key words

antidepressant drugs - drug research - pharmacokinetics

Publication History

Received: 25 February 2020

Accepted: 20 April 2020

Article published online:
13 May 2020

• References

• 1 Riggs DL, Roberts PJ, Chirillo SC. et al. The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J 2003; 22: 1158-1167
• 2 Sinars CR, Cheung-Flynn J, Rimerman RA. et al. Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes. Proc Natl Acad Sci USA 2003; 100: 868-873
• 3 Storer CL, Dickey CA, Galigniana MD. et al. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab 2011; 22: 481-490
• 4 Cioffi DL, Hubler TR, Scammell JG.. Organization and function of the FKBP52 and FKBP51 genes. Curr Opin Pharmacol 2011; 11: 308-313
• 5 Maiarú M, Tochiki KK, Cox MB. et al. The stress regulator FKBP51 drives chronic pain by modulating spinal glucocorticoid signaling. Sci Transl Med 2016; 8: 325ra19
• 6 Häusl AS, Balsevich G, Gassen NC. et al. Focus on FKBP51: A molecular link between stress and metabolic disorders. Mol Metab 2019; 29: 170-181
• 7 Romano S, Xiao Y, Nakaya M. et al. FKBP51 employs both scaffold and isomerase functions to promote NF-kappaB activation in melanoma. Nucleic Acids Res 2015; 43: 6983-6993
• 8 D’Arrigo P, Michele Russo M, Rea A. et al. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. Oncotarget 2017; 8: 68291-68304
• 9 Feng X, Sippel C, Bracher A. et al. Structure-affinity relationship analysis of selective FKBP51 ligands. J Med Chem 2015; 58: 7796-7806
• 10 Gaali S, Kirschner A, Cuboni S. et al. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol 2015; 11: 33-37
• 11 Hartmann J, Wagner KV, Gaali S. et al. Pharmacological inhibition of the psychiatric risk factor FKBP51 has anxiolytic properties. J Neurosci 2015; 35: 9007-9016
• 12 Romano S, Xiao Y, Nakaya M. et al. FKBP51 employs both scaffold and isomerase functions to promote NF-kappaB activation in melanoma. Nucleic Acids Res 2015; 43: 6983-6993
• 13 Fabian AK, März A, Neimanis S. et al. InterAKTions with FKBPs - Mutational and pharmacological exploration. PLoS One 2013; 8: e57508
• 14 US DHHS, FDA, CDER, CVM Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM); 2018; Rockville, MD, USA.